Akebia Therapeutics (AKBA) Common Equity: 2016-2025
Historic Common Equity for Akebia Therapeutics (AKBA) over the last 10 years, with Sep 2025 value amounting to $41.6 million.
- Akebia Therapeutics' Common Equity rose 182.52% to $41.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $41.6 million, marking a year-over-year increase of 182.52%. This contributed to the annual value of -$49.2 million for FY2024, which is 60.82% down from last year.
- Akebia Therapeutics' Common Equity amounted to $41.6 million in Q3 2025, which was up 42.32% from $29.2 million recorded in Q2 2025.
- Over the past 5 years, Akebia Therapeutics' Common Equity peaked at $213.9 million during Q1 2021, and registered a low of -$1.6 billion during Q3 2022.
- Moreover, its 3-year median value for Common Equity was -$27.3 million (2024), whereas its average is -$16.5 million.
- Per our database at Business Quant, Akebia Therapeutics' Common Equity crashed by 1,230.85% in 2022 and then surged by 190.18% in 2025.
- Quarterly analysis of 5 years shows Akebia Therapeutics' Common Equity stood at $74.0 million in 2021, then crashed by 92.93% to $5.2 million in 2022, then crashed by 684.78% to -$30.6 million in 2023, then plummeted by 60.82% to -$49.2 million in 2024, then spiked by 182.52% to $41.6 million in 2025.
- Its Common Equity stands at $41.6 million for Q3 2025, versus $29.2 million for Q2 2025 and $24.6 million for Q1 2025.